25 May 2020
EMA/CVMP/242131/2020
Committee for Medicinal Products for Veterinary Use

Summary of opinion[1] (post-authorisation)

Leucofeligen FeLV/RCP

Common name: Feline calicivirosis vaccine (inactivated), feline viral rhinotrachieitis, feline infectious enteritis (feline panleucopenia) vaccine (live) feline leukaemia vaccine (live recombinant)

On 20 May 2020, the Committee for Medicinal Products for Veterinary Use (CVMP) adopted a positive opinion[2], recommending the granting of a variation to the terms of the marketing authorisation for the veterinary medicinal product Leucofeligen FeLV/RCP. The marketing authorisation holder for this veterinary medicinal product is Virbac S.A.

Leucofeligen FeLV/RCP is currently authorised as lyophilisate and suspension for suspension for injection. The variation concerns to change the onset of immunity for the calicivirus component of the vaccine from 4 weeks after primary vaccination to 3 weeks after first vaccine injection of primary vaccination.

Detailed conditions for the use of this product are described in the updated summary of product characteristics (SPC), for which an updated version reflecting the changes will be published in the revised European public assessment report (EPAR) and will be available in all official European Union languages after the variation to the marketing authorisation has been granted by the European Commission.

[1] Summaries of opinion are published without prejudice to the Commission Decision.
[2] Applicants may appeal any CVMP opinion, provided they notify the European Medicines Agency in writing of their intention to appeal within 15 days of receipt of the opinion.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union